LifeStance Health Group (NASDAQ:LFST) Announces Quarterly Earnings Results

LifeStance Health Group (NASDAQ:LFST) issued its quarterly earnings data on Thursday. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03, Briefing.com reports. LifeStance Health Group had a return on equity of 1.55% and a net margin of 1.55%.The company had revenue of $403.48 million during the quarter, compared to analysts’ expectations of $387.46 million. LifeStance Health Group’s revenue was up 21.2% on a year-over-year basis.

Here are the key takeaways from LifeStance Health Group’s conference call:

• Q1 outperformance: Revenue grew 21% to $403M and adjusted EBITDA rose 48% to $51M, and management raised full‑year guidance to $1.64–$1.68B revenue and $200–$220M adjusted EBITDA while returning $49M in buybacks and ending the quarter with $195M cash.
• Clinician scale and productivity: LifeStance added 309 clinicians to reach 8,349 (11% growth), with visits up 18% to 2.5M and visits per average clinician improving 7% year‑over‑year, driven by durable productivity initiatives.
• Technology and AI focus: The company is deploying AI tools (scheduling, documentation, RPA) to improve access and efficiency and plans a new EHR implementation beginning this year with a 2027 transition to enable scalable AI integration and margin improvement.
• Growth strategy combines de novo expansion (guiding 20–30 new centers in 2026) with a renewed, disciplined tuck‑in M&A program — two small market entries closed in Q1 that establish new footprints for 2027+ growth.
• Clinical outcomes and patient satisfaction: Published outcomes from ~180,000 patients show ~75% achieved clinically significant improvements in anxiety/depression, and the network averages >4.7 stars across 575 centers, supporting differentiation with payers and referral partners.

LifeStance Health Group Price Performance

NASDAQ:LFST traded down $1.14 during mid-day trading on Friday, reaching $7.72. 24,975,660 shares of the company were exchanged, compared to its average volume of 4,897,221. LifeStance Health Group has a 12 month low of $3.74 and a 12 month high of $8.89. The company has a fifty day moving average of $6.80 and a 200 day moving average of $6.68. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.17. The stock has a market cap of $2.99 billion, a PE ratio of 128.58 and a beta of 1.20.

Analyst Upgrades and Downgrades

LFST has been the subject of a number of recent analyst reports. Zacks Research upgraded shares of LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 27th. Wall Street Zen upgraded shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Barclays raised their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a report on Friday, March 6th. KeyCorp boosted their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Finally, Canaccord Genuity Group increased their price target on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, LifeStance Health Group currently has an average rating of “Buy” and a consensus target price of $10.00.

Insiders Place Their Bets

In other news, Director Robert Bessler sold 62,147 shares of LifeStance Health Group stock in a transaction on Friday, April 24th. The stock was sold at an average price of $7.05, for a total value of $438,136.35. Following the completion of the sale, the director directly owned 1,274,448 shares of the company’s stock, valued at approximately $8,984,858.40. This trade represents a 4.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Darren M. Black sold 4,314,939 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $7.01, for a total value of $30,247,722.39. Following the transaction, the director directly owned 29,209,776 shares in the company, valued at $204,760,529.76. This trade represents a 12.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 4,389,939 shares of company stock worth $30,775,881 over the last quarter. Corporate insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Orion Porfolio Solutions LLC acquired a new position in LifeStance Health Group in the fourth quarter valued at approximately $88,000. Xponance LLC grew its holdings in LifeStance Health Group by 26.4% during the 4th quarter. Xponance LLC now owns 13,144 shares of the company’s stock worth $93,000 after acquiring an additional 2,745 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in shares of LifeStance Health Group by 569.1% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 12,024 shares of the company’s stock valued at $85,000 after acquiring an additional 10,227 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of LifeStance Health Group by 467.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 20,507 shares of the company’s stock valued at $106,000 after purchasing an additional 16,893 shares during the period. Finally, Vident Advisory LLC lifted its stake in shares of LifeStance Health Group by 12.7% in the 2nd quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after purchasing an additional 2,447 shares during the period. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group announced that its Board of Directors has approved a share repurchase program on Wednesday, February 25th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3.6% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Key Headlines Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: LifeStance posted a Q1 earnings beat and raised revenue guidance for both Q2 and full-year 2026, signaling stronger-than-expected business momentum.
• Positive Sentiment: BTIG increased its price target on LFST to $12 and reiterated a Buy rating, which may support investor confidence. Benzinga
• Positive Sentiment: Multiple brokerages now view LFST favorably, with consensus recommendations remaining in Buy territory.
• Neutral Sentiment: LifeStance announced a secondary offering of 35 million shares by existing stockholders; the company is not receiving proceeds, but the move can create trading overhang and volatility. GlobeNewswire
• Negative Sentiment: The secondary share sale may pressure the stock in the near term because it increases potential supply, even though LifeStance itself is not issuing new shares.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.